Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.090 USD | -5.22% | +4.81% | -46.57% |
09-12 | Scilex Gets Drug Distributor Accreditation from National Association of Boards of Pharmacy | MT |
09-03 | Scilex Unit Semnur Pharmaceuticals, Denali Capital Sign Merger Agreement | MT |
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | - | -28.1 | -38.49 | -70.16 |
Return on Total Capital | - | - | 62.06 | 201.05 | 1.93K |
Return On Equity % | - | - | 48.38 | 24.9 | 167.27 |
Return on Common Equity | - | - | 48.38 | 24.9 | 244.29 |
Margin Analysis | |||||
Gross Profit Margin % | 72.41 | 90.88 | 88.4 | 71.61 | 66.45 |
SG&A Margin | 307.59 | 182.39 | 161.52 | 170.62 | 255.95 |
EBITDA Margin % | -283.57 | -133.62 | -102.37 | -122.71 | -216.68 |
EBITA Margin % | -283.75 | -133.79 | -102.5 | -122.82 | -216.77 |
EBIT Margin % | -301.4 | -149.65 | -114.44 | -133.13 | -225.55 |
Income From Continuing Operations Margin % | -849.11 | -201.69 | -282.35 | -61.43 | -244.59 |
Net Income Margin % | -849.11 | -201.69 | -282.35 | -61.43 | -244.59 |
Net Avail. For Common Margin % | -849.11 | -201.69 | -282.35 | -61.43 | -357.22 |
Normalized Net Income Margin | -306.93 | -126.2 | -151.59 | -85.44 | -143.24 |
Levered Free Cash Flow Margin | - | - | 156.08 | -271.75 | 71.83 |
Unlevered Free Cash Flow Margin | - | - | 154.31 | -264.23 | 73.12 |
Asset Turnover | |||||
Asset Turnover | - | - | 0.39 | 0.46 | 0.5 |
Fixed Assets Turnover | - | - | 13.53 | 18.96 | 16.79 |
Receivables Turnover (Average Receivables) | - | - | 2.29 | 2.14 | 1.67 |
Inventory Turnover (Average Inventory) | - | - | 1.96 | 5.48 | 5.61 |
Short Term Liquidity | |||||
Current Ratio | - | 0.29 | 0.14 | 0.66 | 0.19 |
Quick Ratio | - | 0.23 | 0.11 | 0.52 | 0.15 |
Operating Cash Flow to Current Liabilities | - | -0.4 | -0.17 | -0.47 | -0.08 |
Days Sales Outstanding (Average Receivables) | - | - | 159.64 | 170.36 | 217.99 |
Days Outstanding Inventory (Average Inventory) | - | - | 186.17 | 66.6 | 65.08 |
Average Days Payable Outstanding | - | - | 448.17 | 241.75 | 486.92 |
Cash Conversion Cycle (Average Days) | - | - | -102.37 | -4.79 | -203.85 |
Long Term Solvency | |||||
Total Debt/Equity | - | -97.84 | -69.12 | 3.89 | -74.28 |
Total Debt / Total Capital | - | -4.54K | -223.85 | 3.75 | -288.84 |
LT Debt/Equity | - | -77.15 | -43.19 | 1.84 | -11.15 |
Long-Term Debt / Total Capital | - | -3.58K | -139.86 | 1.77 | -43.34 |
Total Liabilities / Total Assets | - | 273.84 | 387.27 | 58.12 | 270.7 |
EBIT / Interest Expense | -3.75 | -2.69 | -3.05 | -5.27 | -98.72 |
EBITDA / Interest Expense | -3.53 | -2.33 | -2.67 | -4.81 | -93.81 |
(EBITDA - Capex) / Interest Expense | -3.57 | -2.33 | -2.67 | -4.81 | -93.83 |
Total Debt / EBITDA | - | -4.53 | -4.92 | -0.03 | -1.28 |
Net Debt / EBITDA | - | -4.38 | -4.78 | 0.02 | -1.24 |
Total Debt / (EBITDA - Capex) | - | -4.53 | -4.92 | -0.03 | -1.28 |
Net Debt / (EBITDA - Capex) | - | -4.37 | -4.78 | 0.02 | -1.24 |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | 12.01 | 32.92 | 21.45 | 22.9 |
Gross Profit, 1 Yr. Growth % | - | 40.58 | 29.29 | -1.61 | 14.04 |
EBITDA, 1 Yr. Growth % | - | -47.22 | 1.84 | 45.58 | 117.01 |
EBITA, 1 Yr. Growth % | - | -47.19 | 1.84 | 45.52 | 116.91 |
EBIT, 1 Yr. Growth % | - | -44.38 | 1.64 | 41.29 | 108.22 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | -73.39 | 86.08 | -73.58 | 389.35 |
Net Income, 1 Yr. Growth % | - | -73.39 | 86.08 | -73.58 | 389.35 |
Normalized Net Income, 1 Yr. Growth % | - | -53.94 | 59.67 | -31.55 | 106.04 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | -74.71 | 86.86 | -74.02 | 636.22 |
Accounts Receivable, 1 Yr. Growth % | - | - | 8.7 | 48.84 | 62.92 |
Inventory, 1 Yr. Growth % | - | - | 123.76 | -46.21 | 205.81 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | -16.38 | -9.72 | 92.59 |
Total Assets, 1 Yr. Growth % | - | - | -4.38 | 11.03 | 17.08 |
Tangible Book Value, 1 Yr. Growth % | - | - | 39.68 | -93.54 | 1.15K |
Common Equity, 1 Yr. Growth % | - | - | 58.01 | -116.19 | -577.25 |
Cash From Operations, 1 Yr. Growth % | - | -47.93 | -8.89 | -25.84 | -2.59 |
Capital Expenditures, 1 Yr. Growth % | - | -95.72 | - | - | 328.57 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | - | -311.45 | -132.48 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | - | -307.96 | -134.01 |
Compound Annual Growth Rate Over Two Years | |||||
Total Revenues, 2 Yr. CAGR % | - | - | 22.02 | 27.06 | 22.17 |
Gross Profit, 2 Yr. CAGR % | - | - | 34.82 | 12.79 | 5.93 |
EBITDA, 2 Yr. CAGR % | - | - | -26.69 | 21.76 | 77.75 |
EBITA, 2 Yr. CAGR % | - | - | -26.66 | 21.74 | 77.67 |
EBIT, 2 Yr. CAGR % | - | - | -24.81 | 19.84 | 71.52 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | -29.64 | -29.88 | 13.71 |
Net Income, 2 Yr. CAGR % | - | - | -29.64 | -29.88 | 13.71 |
Normalized Net Income, 2 Yr. CAGR % | - | - | -14.25 | 4.54 | 18.76 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | -31.26 | -30.46 | 38.3 |
Accounts Receivable, 2 Yr. CAGR % | - | - | - | 27.2 | 55.72 |
Inventory, 2 Yr. CAGR % | - | - | - | 9.7 | 28.25 |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | - | -13.12 | 31.86 |
Total Assets, 2 Yr. CAGR % | - | - | - | 3.04 | 14.02 |
Tangible Book Value, 2 Yr. CAGR % | - | - | - | -69.96 | -10.16 |
Common Equity, 2 Yr. CAGR % | - | - | - | -49.43 | -12.11 |
Cash From Operations, 2 Yr. CAGR % | - | - | -31.12 | -17.8 | -15.01 |
Capital Expenditures, 2 Yr. CAGR % | - | - | - | -47.08 | - |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | - | -17.12 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | - | -15.9 |
Compound Annual Growth Rate Over Three Years | |||||
Total Revenues, 3 Yr. CAGR % | - | - | - | 21.83 | 25.66 |
Gross Profit, 3 Yr. CAGR % | - | - | - | 21.38 | 13.2 |
EBITDA, 3 Yr. CAGR % | - | - | - | -7.85 | 47.63 |
EBITA, 3 Yr. CAGR % | - | - | - | -7.84 | 47.59 |
EBIT, 3 Yr. CAGR % | - | - | - | -7.22 | 44.07 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | -49.24 | 34 |
Net Income, 3 Yr. CAGR % | - | - | - | -49.24 | 34 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | -20.45 | 31.07 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | -43.25 | 52.69 |
Accounts Receivable, 3 Yr. CAGR % | - | - | - | - | 38.13 |
Inventory, 3 Yr. CAGR % | - | - | - | - | 54.39 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | - | 13.28 |
Total Assets, 3 Yr. CAGR % | - | - | - | - | 7.52 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | - | 4.08 |
Common Equity, 3 Yr. CAGR % | - | - | - | - | 6.87 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | -29.4 | -13.01 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | -77.11 | 6.27 |